Treatment

The phase 3 MANGROVE trial showed that a chemotherapy-free combination of zanubrutinib (Brukinsa) and rituximab (Rituxan) significantly improved progression-free survival compared with standard chemoimmunotherapy as a first-line treatment for mantle cell lymphoma (MCL). The combination reduced the risk of disease progression or death by 43%. Overall survival data are still early but currently favor the zanubrutinib group. […]

The first planned interim analysis of the phase 2/3 MIRACLE trial showed that adding liposomal annamycin to high-dose cytarabine (HiDAC) produced higher remission rates than HiDAC alone in patients with relapsed or refractory acute myeloid leukemia (AML). After one treatment cycle, complete remission rates were 43% with the 190 mg/m² annamycin dose and 36% with the 230 mg/m² dose,

The phase 3 EPCORE DLBCL-4 trial found that a chemotherapy-free combination of epcoritamab (Epkinly) and lenalidomide (Revlimid) significantly improved progression-free survival compared with R-GemOx chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The treatment reduced the risk of disease progression or death by 56%–60%, depending on the analysis. No new safety concerns were identified,

The phase 3 TRIDENT trial found that starting Tumor Treating Fields (TTFields) during chemoradiation did not improve overall survival for patients with newly diagnosed glioblastoma compared with the current standard of starting treatment during the maintenance phase. The global study enrolled 981 patients. Median overall survival was 17.7 months in the early-start group and 17.5

Myriad Genetics has expanded the availability of its Precise™ MRD Test for patients with breast, colorectal, and renal cancers. The personalized blood test uses whole-genome sequencing to track up to 1,000 tumor-specific genetic changes, helping detect minimal residual disease (MRD), even in cancers that release very little DNA into the bloodstream. The expansion is supported

The National Comprehensive Cancer Network (NCCN) has updated its bladder cancer guidelines to recommend considering circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing after bladder removal surgery for patients with muscle-invasive bladder cancer (MIBC). This is the first time the NCCN has recognized ctDNA-MRD as both a prognostic and predictive biomarker for this disease.

Patients with previously treated metastatic colorectal cancer may benefit from a new combination therapy of zanzalintinib and the immunotherapy drug Tecentriq, according to results from the Phase 3 STELLAR-303 trial. The study enrolled 901 patients whose cancer had progressed after standard treatments. Among all patients in the trial, the combination reduced the risk of death

A first-in-human Phase 1 study presented at the 2026 EHA Congress has reported encouraging results for CT0596, an off-the-shelf CAR T-cell therapy designed for patients with heavily pretreated relapsed or refractory multiple myeloma and primary plasma cell leukemia. Unlike traditional CAR T-cell treatments that are made from a patient’s own cells, CT0596 uses donor cells

Researchers have identified a promising new way to weaken pancreatic cancer by targeting a protein called IL1RAP. Pancreatic tumors depend on an inflammatory network within their surrounding environment to grow, evade the immune system, and resist treatments such as chemotherapy and immunotherapy. IL1RAP acts as a key control point in this network, and blocking it

For patients with KRAS-mutant metastatic colorectal cancer whose disease progresses after two lines of treatment, third-line therapies can extend survival, but the benefits are often measured in months. As a result, doctors must carefully weigh treatment effectiveness, side effects, and quality of life when selecting therapy. Two commonly used options are trifluridine/tipiracil (Lonsurf) plus bevacizumab